MENLO PARK, Calif., March 17 /PRNewswire/ -- Apieron, Inc.
(http://www.apieron.com) announced today that the Insight eNO system has received
clearance to market by the U.S. Food and Drug Administration.

The Insight eNO system measures exhaled nitric oxide (eNO), which is a
well-established indicator of airway inflammation and asthma control. The
Insight system is a highly accurate device, expressly designed for the
physician's office. It is non-invasive, safe, easy to use, and provides
results in less than a minute. Apieron's unique biosensor detects trace
amounts of nitric oxide molecules in a single human breath utilizing a
proprietary technology. Current methods and techniques used to diagnose,
monitor and treat asthma are costly, time-consuming and cumbersome.
Physician office measurement of eNO is a much-awaited breakthrough in
medical technology that provides physicians with a reliable tool to measure
their patients' respiratory inflammation better than ever before.
Measurement of eNO has also been shown to optimize medication therapy and
improve compliance among patients with asthma.

William Berger, M.D., Clinical Professor of Pediatrics, University of
California, Irvine, and Mission Viejo Medical Center, Mission Viejo,
California, stated, "In clinical studies with the Apieron Insight eNO
monitor, I found the ability to easily and accurately measure eNO in the
physician's office to be a major advancement in my care for patients with
persistent asthma."

It is estimated that more than 20 million people in the U.S. suffer
from asthma, making it one of the most common and costly of all diseases.
In fact, every day in America 40,000 people miss school or work due to
asthma and 5,000 people go to the emergency room due to an asthma attack.
One-quarter of all emergency room visits are asthma related and asthma is
the most common chronic childhood disease.

"We are pleased to offer physicians and their patients a reliable,
accurate and affordable asthma measurement and management device," said
Rich Lotti, President and CEO of Apieron, Inc. "We believe this product
will improve the standard of care for patients with asthma enabling
physicians to optimize medical therapy for each patient."

"The availability of simple to use, accurate, and economically feasible
eNO measurement devices now enables physicians to intelligently assess and
manage the key pathologic feature of asthma, airway inflammation," said
Peter B. Boggs, M.D., Clinical Professor of Pediatrics and Medicine, LSU
School of Medicine, Shreveport, Louisiana. "Prior to the availability to
measure eNO, assessing and managing airway inflammation was, for all
practical purposes, little more than a guess! The ability to measure eNO in
the physician's office is 'one giant step' in the care of adults and
children with asthma."

The Insight eNO system includes a small desktop monitor with an
easy-to- read display, trend analysis capabilities and a user-friendly
interface. The system uses disposable, single-use sensors to measure nitric
oxide accurately and non-invasively in less than a minute. Disposable,
single-use breath tubes make it hygienic and convenient for the user to
exhale into the device. Patient data can be stored and maintained in unique
patient cards for trend analysis or downloaded to a printer for insurers'
and patients' files.

About Apieron Inc.

Apieron Inc. is a private, venture-backed medical device company based
in Menlo Park, CA that was formed in early 2001 to develop a simple-to-use,
non- invasive monitor for the measurement of exhaled nitric oxide (eNO) for
the management of asthma. The Apieron biosensor technology platform
utilizes a patented technology that allows for the highly sensitive
detection of selected analytes like eNO. Apieron is committed to
collaborating with physicians and patients to develop innovative medical
solutions to improve quality of life and standards of care.

(Date:11/15/2016)... Research and Markets has announced the addition of the ... their offering. ... The global bioinformatics market ... 6.21 Billion in 2016, growing at a CAGR of 21.1% during ... is driven by the growing demand for nucleic acid and protein ...

(Date:6/22/2016)... -- The American College of Medical Genetics and Genomics was once ... one of the fastest-growing trade shows during the Fastest 50 ... Las Vegas . Winners ... each of the following categories: net square feet of paid ... The 2015 ACMG Annual Meeting was ranked 23 out of ...